Mexiletine Side Effects
Brand Names: Mexitil
Please note - some side effects for Mexiletine may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
|
Side Effects of Mexiletine - for the consumer
Mexiletine
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Mexiletine:
Seek medical attention right away if any of these SEVERE side effects occur when using Mexiletine:Blurred vision; clumsiness; constipation; diarrhea; dizziness or lightheadedness; headache; heartburn; incoordination; nausea; nervousness; stomach discomfort; tremor; vomiting.
TopSevere allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision or other vision problems; chest pain; fainting; fever; irregular, fast, or slow heartbeat; severe dizziness or lightheadedness; severe stomach pain; sore throat; yellowing of the skin or eyes.
For the professional
Mexiletine
Mexiletine hydrochloride commonly produces reversible gastrointestinal and nervous system adverse reactions but is otherwise well tolerated. Mexiletine has been evaluated in 483 patients in one month and three month controlled studies and in over 10,000 patients in a large compassionate use program. Dosages in the controlled studies ranged from 600 to 1200 mg/day; some patients (8%) in the compassionate use program were treated with higher daily doses (1600 to 3200 mg/day). In the three month controlled trials comparing Mexiletine to quinidine, procainamide and disopyramide, the most frequent adverse reactions were upper gastrointestinal distress (41%), lightheadedness (10.5%), tremor (12.6%) and coordination difficulties (10.2%). Similar frequency and incidence were observed in the one month placebo-controlled trial. Although these reactions were generally not serious, and were dose-related and reversible with a reduction in dosage, by taking the drug with food or antacid or by therapy discontinuation, they led to therapy discontinuation in 40% of patients in the controlled trials. Table 1 presents the adverse events reported in the one-month placebo-controlled trial.
Table 1: Comparative Incidence (%) of Adverse Events Among Patients Treated with Mexiletine and Placebo in the 4 Week, Double-blind Crossover Trial
| MexiletineN = 53 | PlaceboN = 49 | |
| Cardiovascular | ||
| Palpitations | 7.5 | 10.2 |
| Chest Pain | 7.5 | 4.1 |
| Increased Ventricular Arrythmia/PVCs | 1.9 | - |
| Digestive | ||
| Nausea/Vomiting/Heartburn | 39.6 | 6.1 |
| Central Nervous System | ||
| Dizziness/Lightheadedness | 26.4 | 14.3 |
| Tremor | 13.2 | - |
| Nervousness | 11.3 | 6.1 |
| Coordination Difficulties | 9.4 | - |
| Changes in Sleep Habits | 7.5 | 16.3 |
| Paresthesias/Numbness | 3.8 | 2.0 |
| Weakness | 1.9 | 4.1 |
| Fatigue | 1.9 | 2.0 |
| Tinnitus | 1.9 | 4.1 |
| Confusion/Clouded Sensorium | 1.9 | 2.0 |
| Other | ||
| Headache | 7.5 | 6.1 |
| Blurred Vision/Visual Disturbances | 7.5 | 2.0 |
| Dyspnea/Respiratory | 5.7 | 10.2 |
| Rash | 3.8 | 2.0 |
| Non-specific Edema | 3.8 | - |
Table 2 presents the adverse reactions occurring in one percent or more of patients in the three month controlled studies.
Table 2: Comparative Incidence (%) of Adverse Events Among Patients Treated with Mexiletine or Control Drugs in the 12 Week Double-blind Trials
| MexiletineN = 430 | QuinidineN = 262 | ProcainamideN = 78 | DisopyramideN = 69 | |
| Cardiovascular | ||||
| Palpitations | 4.3 | 4.6 | 1.3 | 5.8 |
| Chest Pain | 2.6 | 3.4 | 1.3 | 2.9 |
| Angina/Angina-like Pain | 1.7 | 1.9 | 2.6 | 2.9 |
| Increased Ventricular Arrhythmias/PVCs | 1.0 | 2.7 | 2.6 | - |
| Digestive | ||||
| Nausea/Vomiting/ Heartburn | 39.3 | 21.4 | 33.3 | 14.5 |
| Diarrhea | 5.2 | 33.2 | 2.6 | 8.7 |
| Constipation | 4.0 | - | 6.4 | 11.6 |
| Changes in Appetite | 2.6 | 1.9 | - | - |
| Abdominal Pain/Cramps/ Discomfort | 1.2 | 1.5 | - | 1.4 |
| Central Nervous System | ||||
| Dizziness/Lightheadedness | 18.9 | 14.1 | 14.1 | 2.9 |
| Tremor | 13.2 | 2.3 | 3.8 | 1.4 |
| Coordination Difficulties | 9.7 | 1.1 | 1.3 | - |
| Changes in Sleep Habits | 7.1 | 2.7 | 11.5 | 8.7 |
| Weakness | 5.0 | 5.3 | 7.7 | 2.9 |
| Nervousness | 5.0 | 1.9 | 6.4 | 5.8 |
| Fatigue | 3.8 | 5.7 | 5.1 | 1.4 |
| Speech Difficulties | 2.6 | 0.4 | - | - |
| Confusion/Clouded Sensorium | 2.6 | - | 3.8 | - |
| Paresthesias/Numbness | 2.4 | 2.3 | 2.6 | - |
| Tinnitus | 2.4 | 1.5 | - | - |
| Depression | 2.4 | 1.1 | 1.3 | 1.4 |
| Other | ||||
| Blurred Vision/Visual Disturbances | 5.7 | 3.1 | 5.1 | 7.2 |
| Headache | 5.7 | 6.9 | 7.7 | 4.3 |
| Rash | 4.2 | 3.8 | 10.3 | 1.4 |
| Dyspnea/Respiratory | 3.3 | 3.1 | 5.1 | 2.9 |
| Dry Mouth | 2.8 | 1.9 | 5.1 | 14.5 |
| Arthralgia | 1.7 | 2.3 | 5.1 | 1.4 |
| Fever | 1.2 | 3.1 | 2.6 | - |
Less than 1%: Syncope, edema, hot flashes, hypertension, short-term memory loss, loss of consciousness, other psychological changes, diaphoresis, urinary hesitancy/retention, malaise, impotence/decreased libido, pharyngitis, congestive heart failure.
An additional group of over 10,000 patients has been treated in a program allowing administration of Mexiletine hydrochloride under compassionate use circumstances. These patients were seriously ill with the large majority on multiple drug therapy. Twenty-four percent of the patients continued in the program for one year or longer. Adverse reactions leading to therapy discontinuation occurred in 15 percent of patients (usually upper gastrointestinal system or nervous system effects). In general, the more common adverse reactions were similar to those in the controlled trials. Less common adverse events possibly related to Mexiletine use include:
Cardiovascular System
Syncope and hypotension, each about 6 in 1000; bradycardia, about 4 in 1000; angina/angina-like pain, about 3 in 1000; edema, atrioventricular block/conduction disturbances and hot flashes, each about 2 in 1000; atrial arrhythmias, hypertension and cardiogenic shock, each about 1 in 1000.
Central Nervous System
Short-term memory loss, about 9 in 1000 patients; hallucinations and other psychological changes, each about 3 in 1000; psychosis and convulsions/seizures, each about 2 in 1000; loss of consciousness, about 6 in 10,000.
Digestive
Dysphagia, about 2 in 1000; peptic ulcer, about 8 in 10,000; upper gastrointestinal bleeding, about 7 in 10,000; esophageal ulceration, about 1 in 10,000. Rare cases of severe hepatitis/acute hepatic necrosis.
Skin
Rare cases of exfoliative dermatitis and Stevens-Johnson syndrome with Mexiletine treatment have been reported.
Laboratory
Abnormal liver function tests, about 5 in 1000; positive ANA and thrombocytopenia, each about 2 in 1000; leukopenia (including neutropenia and agranulocytosis), about 1 in 1000; myelofibrosis, about 2 in 10,000 patients.
Other
Diaphoresis, about 6 in 1000; altered taste, about 5 in 1000; salivary changes, hair loss and impotence/decreased libido, each about 4 in 1000; malaise, about 3 in 1000; urinary hesitancy/retention, each about 2 in 1000; hiccups, dry skin, laryngeal and pharyngeal changes and changes in oral mucous membranes, each about 1 in 1000; SLE syndrome, about 4 in 10,000.
Hematology
Blood dyscrasias were not seen in the controlled trials but did occur among 10,867 patients treated with Mexiletine in the compassionate use program.
Myelofibrosis was reported in two patients in the compassionate use program; one was receiving long-term thiotepa therapy and the other had pretreatment myeloid abnormalities.
In postmarketing experience, there have been isolated, spontaneous reports of pulmonary changes including pulmonary infiltration and pulmonary fibrosis during Mexiletine therapy with or without other drugs or diseases that are known to produce pulmonary toxicity. A causal relationship to Mexiletine therapy has not been established. In addition, there have been isolated reports of drowsiness, nystagmus, ataxia, dyspepsia, hypersensitivity reaction, and exacerbation of congestive heart failure in patients with pre-existing compromised ventricular function. There have been rare reports of pancreatitis associated with Mexiletine treatment.
TopMore resources:
Mexiletine - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.



